Join BIOCYTOGEN at AET (Antibody Engineering & Therapeutics) US 2024
We’re thrilled to announce our participation as an exhibitor at AET (Antibody Engineering & Therapeutics) US 2024! From December 15th to 18th in San Diego,…
Read more
Join BIOCYTOGEN at BioFit 2024
We’re thrilled to announce our participation as an exhibitor at BioFIT 2024! From December 3rd to 4th in Lille, France, this prestigious event will bring…
Read more
Join BIOCYTOGEN at 2nd Cell Therapy For Autoimmune Disease Summit
We’re thrilled to announce our participation as an exhibitor at the 2nd Cell Therapy For Autoimmune Disease Summit! From December 2nd to 3rd in Philadelphia,…
Read more
Join BIOCYTOGEN at Sino-American Pharmaceutical Professionals Association (SAPA), Connecticut 2024
We’re thrilled to announce our participation as an exhibitor at the Sino-American Pharmaceutical Professionals Association (SAPA) Connecticut 2024 conference. Taking place on December 7th in…
Read more
Behind the Scene: Meet Brent, The Chicken-Raising, Mouse-Managing Expert at Biocytogen
Meet Brent, a breeding project lead at Biocytogen whose day-to-day work involves much more than managing mouse colonies—he also brings a little “farm fresh” touch…
Read more
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen’s potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034) This milestone further…
Read more
The Future of Cancer Treatment: Cutting-Edge Advances in Immuno-Oncology
Imagine a future where cancer treatment is as precise and personalized as it is powerful, where the body’s own defenses are guided to hunt down…
Read more
Breaking Down Barriers in Drug Development: Key Takeaways from Biocytogen’s Maryland Forum
One of the biggest challenges in personalized medicine is not only proving efficacy but also ensuring feasible manufacturing at scale. Unlike traditional therapies developed for…
Read more
GSK’s $300M Acquisition of Chimagen’s CMG1A46: A Deep Dive into B Cell-Targeted Trispecific T Cell Engagers
On October 29, GSK made headlines with a $300 million upfront payment to acquire Chimagen Biosciences’ clinical-stage asset, CMG1A46, a dual-target CD19/CD20 trispecific T cell…
Read more
Join BIOCYTOGEN at 7th SCBA Hepatology Division & CALS Annual Symposium
We are thrilled to announce our participation as an exhibitor at the SCBA Hepatology Division & CALS Annual Symposium 2024. Taking place from November 13th…
Read more